Allopurinol pharmacogenetics: assessment of potential clinical usefulness.
Pharmacogenomics
; 12(12): 1741-9, 2011 Dec.
Article
em En
| MEDLINE
| ID: mdl-22118056
ABSTRACT
Use of pharmacogenetics to inform treatment decisions remains a priority for clinicians, patients and public health agencies. We previously developed a framework for systematically assessing whether pharmacogenetic test information would likely bring value to clinical decision-making and enjoy practical uptake. We applied this tool to allopurinol to determine potential usefulness of HLA genetic information in assessing risk for allopurinol-induced severe cutaneous adverse reactions. We quantified allopurinol use data and the magnitude of adverse event signals using US FDA databases, reviewed reported cases of allopurinol-associated severe cutaneous adverse reactions to assess whether clinical subtypes of patients could be identified, performed pooled analyses of associations between HLA variation and allopurinol-induced severe cutaneous adverse reactions and described considerations in clinical implementation of allopurinol pharmacogenetics.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Dermatopatias
/
Variação Genética
/
Alopurinol
/
Supressores da Gota
/
Testes Genéticos
/
Antígenos HLA
Idioma:
En
Ano de publicação:
2011
Tipo de documento:
Article